chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Feeling abnormal
Clinical narrative: Brain fog; This is a spontaneous report from a non-contactable consumer, the patient. A 39-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 04Apr2021 (at the age of 39-year-old) as a single dose for COVID-19 immunisation. Medical history included none. The patient had no known allergies to medications, food, or other products. The patient did not receive any medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 04Apr2021, the patient experienced brain fog. Event did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. The patient did not receive any treatment for the event. The clinical outcome of the event brain fog was recovering at the time of report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Throat tightness, Urticaria
Clinical narrative: itching all over; hives on chest; thickness feeling in throat; This is a spontaneous report from a non-contactable consumer, the patient. A 50-year-old female patient received the second the dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8783) via an unspecified route of administration in the left arm on 02Apr2021 at 19:45 (at the age of 50-years-old), as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient did not have allergies to medications, food, or other products. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206) via an unspecified route of administration in the left arm on 12Mar2021 at 19:45 (at the age of 50-years-old), as a single dose for COVID-19 immunisation. The patient did not receive any other vaccination within four weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19.  On 02Apr2021 at 21:30, within 1.5 hours of second shot, the patient experienced itching all over, hives on chest and thickness feeling in throat. The patient was treated with diphenhydramine (BENADRYL) 50mg for the reported adverse events. The events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. The clinical outcome of the events itching all over, hives on chest and thickness feeling in throat was recovering at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Myalgia, Palpitations, SARS-CoV-2 test
Clinical narrative: Heart Palpitations; Fatigue; Muscle aches; Headache; This is a spontaneous report from a contactable consumer, the patient.  A 33-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6198) via an unspecified route of administration on 03Mar2021 at 10:00 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. Medical history included stomach gastritis reportedly weeks after. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medications within two weeks prior to the vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received penicillin and experienced allergy. On 03Mar2021 at 11:30, after 1-2 hours of vaccination, the patient experienced heart palpitations, muscle ache, fatigue and headache. On 03Mar2021 at 11:32, heart palpitations resolved after lasting for 2 minutes. On 04Mar2021, muscle ache, fatigue and headache resolved after lasting for one day. The patient called to report heart palpitations but this was considered normal yet patient felt there was no mention of this as a possible side effect. On 17Mar2021, post vaccination, the patient underwent oral swab test and the result was negative. The adverse events neither resulted in doctor or other healthcare professional office/clinic visit nor emergency room/department or urgent care. It was unknown whether the patient received treatment for the reported adverse events. The clinical outcome of the events heart palpitations resolved on 03Mar2021 at 11:32, muscle ache, fatigue  and headache were resolved on 04Mar2021. The patient had not received the second dose at the time of reporting.  No follow-up attempts are needed. No further information is expected.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia oral, Paraesthesia, Paraesthesia oral
Clinical narrative: Tingling in my right ring and pinky fingers; Tingling in the right jaw that started near the ear, the front of the mouth, including the tip of the tongue; Numbness in the right jaw started near the ear progressed down my teeth toward the front of my mouth; This is a spontaneous report received from a contactable consumer, the patient. A 62-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EN6201), via an unspecified route of administration in the right arm on 06Mar2021 at 11:00 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. Medical history and known allergies were not reported. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient  received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EN6208) via an unspecified route of administration in the left arm on 27Mar2021 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medications within two weeks of vaccination. On 06Mar2021 at 11:00, after about 20 minutes of receiving the first COVID-19 vaccine dose, the patient experienced tingling in her right ring and pinky fingers. Then quickly the patient experienced tingling and numbing in her right jaw that started near the ear and progressed down her teeth toward the front of her mouth including the tip of her tongue. The patient felt like she received a novacaine shot from the dentist. The tingling and numbness continued through out the day into the evening. When the patient retired to sleep, just a bit of numbness on the tongue had remained. Following day the patient experienced additional tingling in that right hand in the ring and pinky fingers. The adverse events did not result in a visit to the doctors or other healthcare professional office or clinic visit and emergency room or department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events tingling in right ring and pinky fingers, tingling in the right jaw that started near the ear, the front of the mouth, including the tip of the tongue, numbness in the right jaw started near the ear progressing down the teeth toward the front of mouth were recovered on an unknown date in 2021.   No follow-up attempts are possible. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site mass, Vaccination site pain
Clinical narrative: Large raised, reddened area around sight of injection. 2 inches in diameter; Large raised, reddened area around sight of injection; Large raised, reddened area around sight of injection. 2 inches in diameter. Painful.; This is a spontaneous report from a non-contactable consumer, the patient. A 30-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 02Apr2021 at 15:45 (at the age of 30-years-old), as a single dose for COVID-19 immunisation. Medical history included COVID-19 on unknown dates. The patient did not receive any concomitant medications. The patient did not have any allergies to medications, food, or other products. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 03Apr2021 at 07:00, the patient experienced large raised, reddened area around site of injection that is 2 inches in diameter, painful and not itchy. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events large raised, reddened area around site of injection that is 2 inches in diameter, painful and not itchy was not recovered at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Pyrexia
Clinical narrative: I am on day 12 of low-grade fever.; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the arm left on 25Mar2021 at 10:00 (at the age of 37-year-old) as a single dose for COVID-19 immunisation. Medical history included asthma from an unknown date. Concomitant medications included fluticasone propionate and salmeterol xinafoate (ADVAIR), cetirizine hydrochloride (ZYRTEC) and OTC probiotics from an unknown date for an unknown indication. The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202) in the left arm on 25Feb2021 at 10:00 (at the age of 37-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 25Mar2021 at 13:00 the patient experienced low-grade fever. The highest hit was 100.8 measured with a forehead/temple touch thermometer. Most of the time it would register between 99.7-100.3. The patient generally had a lower than average temperature, something like 98.2. In 2021, the patient was checked for body temperature and the result was 100.8 The patient did not receive any treatment for the event. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. The clinical outcome of the event low-grade fever was not recovered at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Parosmia
Clinical narrative: Metallic smell in my nose; This is a spontaneous report from a contactable healthcare professional, the patient. A 48-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 05Apr2021 at 15:30 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient was not allergic to medications, food, or other products. Concomitant medication included drospirenone, ethinylestradiol betadex clathrate (YAZ) from an unknown date and for unspecified indication. Prior to the vaccination, the patient was diagnosed with COVID-19 on an unknown date. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 05Apr2021 at 18:15 2hours after the vaccination the patient experienced metallic smell in her nose. The patient did not receive any treatment for the reported adverse event. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event metallic smell in her nose was not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Fatigue, Pain in extremity, Vertigo
Clinical narrative: Vertigo; Dizziness; Arm pain; Fatigue; This is a spontaneous report from a non-contactable consumer, the patient. A 61-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 04Apr2021 at 13:30 (at the age of 61-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot Number: UNKNOWN) via an unspecified route of administration on unknown date  as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 05Apr2021 the patient experienced vertigo, dizziness, arm pain and fatigue. The patient did not receive any treatment for the events. The events didn't result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events vertigo, dizziness, arm pain and fatigue were unknown.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Vaccination site pain
Clinical narrative: Muscle pain at injection site; Muscle pain at injection site; This is a spontaneous report from a non-contactable physician. A 55-years-old female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown) via an unspecified route of administration on 04Apr2021 at 17:00 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 05Apr2021, the patient experienced muscle pain (muscle pain), at injection site (vaccination site pain). No therapeutic measures were taken as a result of reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events muscle pain and vaccination site pain were not recovered.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Conjunctivitis
Clinical narrative: Conjunctivitis- pink eye; This is a spontaneous report from a non-contactable consumer, the patient. A 60-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6199), via an unspecified route of administration in the left arm on 09Mar2021 at 12:45 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. The patient also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727), via an unspecified route of administration in the left arm on 30Mar2021 at 15:30 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history included rheumatoid arthritis. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On an unspecified date in Mar2021, the patient experienced conjunctivitis- pink eye. The patient reported that this event occurred for both the doses of the vaccine. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the event experienced. The clinical outcome of the event conjunctivitis- pink eye was not resolved at the time of this report.    No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: M
Vaccine: COVID19
Symptoms: Oropharyngeal pain, Pharyngeal swelling, SARS-CoV-2 test, Taste disorder
Clinical narrative: swollen throat; Bad taste in mouth; sore throat; This is a spontaneous report received from a non-contactable consumer, the patient. A 42-year-old male patient received the unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration on 28Mar2021 at 11:30 (at the age of 42-years-old), as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient had not received any other vaccines within 4 weeks prior to the COVID vaccine. On 29Mar2021, the patient experienced throat swelling, sore throat and bad taste in the mouth. The adverse event resulted in emergency room or department or urgent care. The patient was tested for COVID-19 post-vaccination. The patient underwent a SARS-CoV-2 nasal swab test on 04Apr2021, and the result was negative. The patient received pain medicine as the treatment for the adverse events. The clinical outcome of the events throat swelling, sore throat and bad taste in mouth were not recovered at the time of the report.  No follow-up attempts are possible; information about the lot number cannot be obtained.
Age: 63.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Dysphonia, Hot flush, Nasal congestion, Nausea
Clinical narrative: Extreme dizziness; Nausea; Vomiting; Hot flash; Some congestion; Hoarseness; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 01Apr2021 at 14:30 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma, diabetes and penicillin allergy. Concomitant medications were not reported. The patient previously took amoxicillin (MANUFACTURER UNKNOWN) and lisinopril (MANUFACTURER UNKNOWN), both on unknown dates and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 01Apr2021 same day after vaccination (also reported as, on evening of second injection - 02Apr2021), the patient experienced extreme dizziness. nausea, vomiting, hot flash, some congestion and hoarseness for the first time. The patient had sudden recurrence daily of dizziness, nausea and sometimes vomiting. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event extreme dizziness. nausea, vomiting, hot flash, some congestion and hoarseness was not resolved at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 63.0
Sex: M
Vaccine: COVID19
Symptoms: Vomiting
Clinical narrative: Extreme dizziness; Nausea; Vomiting; Hot flash; Some congestion; Hoarseness; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 01Apr2021 at 14:30 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma, diabetes and penicillin allergy. Concomitant medications were not reported. The patient previously took amoxicillin (MANUFACTURER UNKNOWN) and lisinopril (MANUFACTURER UNKNOWN), both on unknown dates and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 01Apr2021 same day after vaccination (also reported as, on evening of second injection - 02Apr2021), the patient experienced extreme dizziness. nausea, vomiting, hot flash, some congestion and hoarseness for the first time. The patient had sudden recurrence daily of dizziness, nausea and sometimes vomiting. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event extreme dizziness. nausea, vomiting, hot flash, some congestion and hoarseness was not resolved at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Herpes zoster
Clinical narrative: Developed shingles on back and chest; This is a spontaneous report from a contactable consumer. A 75-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6207) via an unspecified route of administration in the right arm on 15Mar2021 at 15:45 (at the age of 75-years-old) as single dose for COVID-19 immunisation. Medical history of the patient included diabetes, COPD (chronic obstructive pulmonary disease), stroke, kidney disease and the patient had a history of allergy to cheap gold. The patient received unspecified medications within two weeks prior to the vaccination for an unknown indication. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 25Mar2021, the patient developed shingles on back and chest. The patient received treatment for the events with VALTREX. Adverse event resulted emergency room/department or urgent care. The clinical outcome for the event of developed shingles on back and chest was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Bedridden, Chills, Decreased appetite, Fatigue, Headache
Clinical narrative: Havent been able to getout of bed; My head hurts; Terrible sore throat; No appetite; Fatigue; Chills; Muscular pain; Feeling very sick; This is a spontaneous report from a contactable consumer, the patient. A 24-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the arm right on 31Mar2021 at 11:30 (at the age of 24-years-old) as a single dose for COVID-19 immunisation. Medical history was reported as no.  The patient had no known allergies to medications, food, or other products. The patient did not receive any other medicines within two weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Since the vaccination, patient was tested for COVID-19. On 05Apr2021, the patient had nasal swab COVID-19 virus test and the result found to be unknown. The patient received the vaccine on Wednesday 31Mar2021, and started feeling very sick since Friday 02Apr2021. On Monday 05Apr2021, the patient was feeling as sick, it had not gotten any better, and was not been able to get out of bed. The patient's head was hurting, a terrible sore throat, had no appetite, fatigue, chills and muscular pain.  Muscular pain was the only symptom that was getting better. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events malaise, bedridden, headache, sore throat, appetite lost, fatigue, chills and muscular pain was not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Malaise, Myalgia, Oropharyngeal pain, SARS-CoV-2 test
Clinical narrative: Havent been able to getout of bed; My head hurts; Terrible sore throat; No appetite; Fatigue; Chills; Muscular pain; Feeling very sick; This is a spontaneous report from a contactable consumer, the patient. A 24-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the arm right on 31Mar2021 at 11:30 (at the age of 24-years-old) as a single dose for COVID-19 immunisation. Medical history was reported as no.  The patient had no known allergies to medications, food, or other products. The patient did not receive any other medicines within two weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Since the vaccination, patient was tested for COVID-19. On 05Apr2021, the patient had nasal swab COVID-19 virus test and the result found to be unknown. The patient received the vaccine on Wednesday 31Mar2021, and started feeling very sick since Friday 02Apr2021. On Monday 05Apr2021, the patient was feeling as sick, it had not gotten any better, and was not been able to get out of bed. The patient's head was hurting, a terrible sore throat, had no appetite, fatigue, chills and muscular pain.  Muscular pain was the only symptom that was getting better. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events malaise, bedridden, headache, sore throat, appetite lost, fatigue, chills and muscular pain was not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Balance disorder, Dizziness, Dry mouth, Dry throat, Hypopnoea
Clinical narrative: Fell dizziness; I couldn't stand up I was throwing up; my breathing was shallow; Throat was dry; Mouth was dry; Shaking uncontrollably; Heart palpitations; This is a spontaneous report from a contactable other healthcare professional, the patient. A 63-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3302) via an unspecified route of administration in the left arm on 02Apr2021 at 09:15 (at the age of 63-year-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure, shellfish and penicillin allergy. concomitant medications included unspecified blood pressure medicine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021 at 19:30 in the evening, the patient fell dizziness, she couldn't stand up she was throwing up, her breathing was shallow, her throat was dry, her mouth was dry, she was shaking uncontrollably and had to call EMT also was getting heart palpitations. The events resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive any treatment for the events. The clinical outcome of the events fell dizziness, couldn't stand up she was throwing up (balance difficulty), breathing was shallow, throat was dry, mouth was dry, shaking uncontrollably and heart palpitations were recovered on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Palpitations, Tremor
Clinical narrative: Fell dizziness; I couldn't stand up I was throwing up; my breathing was shallow; Throat was dry; Mouth was dry; Shaking uncontrollably; Heart palpitations; This is a spontaneous report from a contactable other healthcare professional, the patient. A 63-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3302) via an unspecified route of administration in the left arm on 02Apr2021 at 09:15 (at the age of 63-year-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure, shellfish and penicillin allergy. concomitant medications included unspecified blood pressure medicine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021 at 19:30 in the evening, the patient fell dizziness, she couldn't stand up she was throwing up, her breathing was shallow, her throat was dry, her mouth was dry, she was shaking uncontrollably and had to call EMT also was getting heart palpitations. The events resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive any treatment for the events. The clinical outcome of the events fell dizziness, couldn't stand up she was throwing up (balance difficulty), breathing was shallow, throat was dry, mouth was dry, shaking uncontrollably and heart palpitations were recovered on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Nausea, Pain, Pyrexia
Clinical narrative: Body aches; Fever; Nausea; Headache; This is a spontaneous report from a contactable consumer, the patient. A 60-years-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: unknown) via an unspecified route of administration in the left arm on 01Apr2021 at 08:00 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism and mild depression. The patient not had known allergies to medications, food or other products. Concomitant medications included levothyroxine sodium (SYNTHROID) and lexoprin(MANUUFACTURER UNKNOWN), both from an unknown date, for an unknown indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: unknown) via an unspecified route of administration in the left arm on 11Mar2021 at 08:15 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 02Apr2021 at 02:00, the patient experienced fever, nausea, headache and body aches. No therapeutic measures were taken as a result of reported event. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fever, nausea, headache and body aches was recovered on an unspecified date in Apr2021.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Sex: M
Vaccine: COVID19
Symptoms: Abdominal discomfort, Fatigue, Frequent bowel movements
Clinical narrative: Stomach issues/ stomach ailment; frequent bowel movements with very small amout of stools; Very tired; This is a spontaneous report from a contactable consumer, the patient. An unspecified aged male patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: unknown) via an unspecified route of administration on 02Apr2021 at 13:45 (age at vaccination was unknown) as a single dose for COVID-19 immunisation. Medical history included allergies (hay Fever). The patient had no known allergies to medications, food or other products. Concomitant medications included amlodipine (MANUFACTURER UNKNOWN), from an unknown date for unknown indication. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 02Apr2021 at 19:30, the patient experienced very tired every day since vaccination, 3 days after vaccination (05Apr2021), the patient experienced stomach issues, (frequent bowel movements with very small amount of stools, as though he had a stomach ailment and was recovering from it. The patient felt much better after he ate something). No therapeutic measures were taken as a result of the reported events. The clinical outcomes of stomach issues, very tired and frequent bowel movements with very small amount of stools were recovering.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 59.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Pyrexia
Clinical narrative: Mild fever; fatigue; This is a spontaneous report from a contactable consumer. A 59-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 03Apr2021 at 18:00 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. Medical history included none. The patient did not have a history of allergies to medications, food, or other products. Concomitant medications were not reported. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 13Mar2021 at 18:00 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 04Apr2021 at 15:00 the patient experienced mild fever and fatigue after second dose. The events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events mild fever and fatigue was recovered on an unknown date in 2021.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Swelling face
Clinical narrative: Swelling by the Jaw; This is a spontaneous report from a non-contactable healthcare professional. A 31-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER7835), via an unspecified route of administration in the left arm on 31Mar2021 at 16:45 (at the age of 31-years-old), as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient did not have any known allergies to medications, food or other products. Concomitant medications included vitamin D (MANUFACTURER UNKNOWN) started on an unknown date for unspecified indication and fish oil capsule (MANUFACTURER UNKNOWN) started on an unknown date for unspecified indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 02Apr2021, the patient experienced swelling by the jaw. No therapeutic measures were taken as a result of the reported event. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event swelling by the jaw was not recovered at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 52.0
Sex: M
Vaccine: COVID19
Symptoms: Pain in extremity, Vaccination site pain, Vaccination site rash
Clinical narrative: Rash at injection site; Soreness at injection site; Arm was sore; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the left arm on 15Mar2021 at 09:45 (at the age of 52-years-old), as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient had no allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 21Mar2021 at 12:00, 6 days after the vaccination, the patient experienced rash and soreness at the injection site. On an unknown date in Mar2021, the patient reported that initially arm was sore for two days, then the patient felt ok until day 6. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. The clinical outcome of the events rash and soreness at the injection site and sore arm were resolved on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Fatigue, Headache, Malaise
Clinical narrative: Tiredness; muscle pain; chills; joint pain; Headache; Fever; injection site pain; Nausea; feeling unwell; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 03Apr2021 at 17:30 (at the age of 60-year-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. It was reported that the patient had no allergies to medications, food, or other products. The patient did not receive any vaccination within four weeks prior to the COVID-19 vaccine. Concomitant medications included progesterone (MANUFACTURER UNKNOWN), dextromethorphan hydrobromide and guaifenesin (ROBITUSSIN DM) and azithromycin (MANUFACTURER UNKNOWN) started on an unknown date for an unknown indication. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 04Apr2021 at 6:00, the patient experienced tiredness, muscle pain, chills, joint pain, headache, fever, vaccination site pain, nausea and malaise. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events tiredness, muscle pain, chills, joint pain, headache, fever, vaccination site pain, nausea and malaise were recovered on an unknown date in 2021.  No follow-up attempts are needed; information about the lot number cannot be obtained.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Nausea, Pyrexia, Vaccination site pain
Clinical narrative: Tiredness; muscle pain; chills; joint pain; Headache; Fever; injection site pain; Nausea; feeling unwell; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 03Apr2021 at 17:30 (at the age of 60-year-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. It was reported that the patient had no allergies to medications, food, or other products. The patient did not receive any vaccination within four weeks prior to the COVID-19 vaccine. Concomitant medications included progesterone (MANUFACTURER UNKNOWN), dextromethorphan hydrobromide and guaifenesin (ROBITUSSIN DM) and azithromycin (MANUFACTURER UNKNOWN) started on an unknown date for an unknown indication. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 04Apr2021 at 6:00, the patient experienced tiredness, muscle pain, chills, joint pain, headache, fever, vaccination site pain, nausea and malaise. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events tiredness, muscle pain, chills, joint pain, headache, fever, vaccination site pain, nausea and malaise were recovered on an unknown date in 2021.  No follow-up attempts are needed; information about the lot number cannot be obtained.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Axillary pain, Body temperature, Discomfort, Lymphadenopathy, Pain in extremity
Clinical narrative: Left arm pit accompanied by pain and discomfort.; Left arm pit accompanied by pain and discomfort.; Severe swelling of the lymph node; Fever of 37.9; Severe pain in left arm; This is a spontaneous report received from a non-contactable consumer (patient). A 46-year-old non-pregnant female patient received BNT162B2 (COVID-19 VACCINE-MANUFACTURER UNKNOWN; Lot Number: ew0151), via an unspecified route of administration in the arm left on 01Apr2021 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 prior to vaccination on an unspecified date. The patient had history of known allergies to nickel. Concomitant medications included vitamin D (MANUFACTURER UNKNOWN), magnesium (MANUFACTURER UNKNOWN) and ibuprofen (ADVIL); all from an unknown dates taken for unknown indications. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient has not tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient experienced left arm pit accompanied by pain and discomfort on 02Apr2021, at  16:00 with outcome of recovering, severe swelling of the lymph node on 02Apr2021, at 16:00 with outcome of recovering, fever of 37.9 on 02Apr2021, at 16:00 with outcome of recovered on 04Apr2021, severe pain in left arm on 02Apr2021, at 16:00 with outcome of recovering. Details were as follows: on 02Apr2021 at 16:00, 24 hours following the injection, the patient experienced fever of 37.9 which lasted for almost two days. Severe pain in the left arm. Severe swelling of the lymph node in the left arm pit accompanied by pain and discomfort were noted. The lymph was visibly swollen 4 days after the injection. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. The clinical outcomes of the left arm pit accompanied by pain and discomfort, severe swelling of the lymph node and severe pain in left arm was recovering; fever of 37.9 recovered on 04Apr2021.   Pfizer is a marketing authorization holder of BNT162B2 in the country of incidence or the country where the product was purchased (if different). This may be a duplicate report if another marketing authorization holder of BNT162B2 has submitted the same report to the regulatory authorities.  No follow-up attempts are possible. No further information is expected.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Left arm pit accompanied by pain and discomfort.; Left arm pit accompanied by pain and discomfort.; Severe swelling of the lymph node; Fever of 37.9; Severe pain in left arm; This is a spontaneous report received from a non-contactable consumer (patient). A 46-year-old non-pregnant female patient received BNT162B2 (COVID-19 VACCINE-MANUFACTURER UNKNOWN; Lot Number: ew0151), via an unspecified route of administration in the arm left on 01Apr2021 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 prior to vaccination on an unspecified date. The patient had history of known allergies to nickel. Concomitant medications included vitamin D (MANUFACTURER UNKNOWN), magnesium (MANUFACTURER UNKNOWN) and ibuprofen (ADVIL); all from an unknown dates taken for unknown indications. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient has not tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient experienced left arm pit accompanied by pain and discomfort on 02Apr2021, at  16:00 with outcome of recovering, severe swelling of the lymph node on 02Apr2021, at 16:00 with outcome of recovering, fever of 37.9 on 02Apr2021, at 16:00 with outcome of recovered on 04Apr2021, severe pain in left arm on 02Apr2021, at 16:00 with outcome of recovering. Details were as follows: on 02Apr2021 at 16:00, 24 hours following the injection, the patient experienced fever of 37.9 which lasted for almost two days. Severe pain in the left arm. Severe swelling of the lymph node in the left arm pit accompanied by pain and discomfort were noted. The lymph was visibly swollen 4 days after the injection. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. The clinical outcomes of the left arm pit accompanied by pain and discomfort, severe swelling of the lymph node and severe pain in left arm was recovering; fever of 37.9 recovered on 04Apr2021.   Pfizer is a marketing authorization holder of BNT162B2 in the country of incidence or the country where the product was purchased (if different). This may be a duplicate report if another marketing authorization holder of BNT162B2 has submitted the same report to the regulatory authorities.  No follow-up attempts are possible. No further information is expected.